Alzheimers Disease Therapeutics Market by Drug Class, Distribution Channel, and Geography - Forecast and Analysis 2023-2027

The alzheimer's disease therapeutics market is estimated to grow at a CAGR of 8.91% between 2022 and 2027. The size of the market is forecast to increase by USD 4,391.9 million. The growth of the market depends on several factors, including availability, research, and development of novel biomarkers, increasing awareness of alzheimer's disease, and a strong pipeline coupled with approval of therapeutics. 

This report extensively covers market segmentation by drug class (cholinesterase inhibitors, n-methyl-d-aspartate receptor antagonist, and others), distribution channel (hospital pharmacy, retail pharmacy, and e-commerce pharmacy), and geography (North America, Europe, Asia, and Rest of World). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

What will be the size of the Alzheimer's Disease Therapeutics Market During the Forecast Period?

To learn more about this report, View Report Sample

Alzheimer's Disease Therapeutics Market: Key Drivers, Trends, Challenges, and Customer Landscape

The increasing awareness of alzheimer's disease is notably driving the market growth, although factors such as challenges associated with the diagnosis of alzheimer's disease may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Alzheimer's Disease Therapeutics Market Driver

The increasing awareness of alzheimer's disease is notably driving the market growth. Many people who have the disease are unaware of it because some of its symptoms, like memory loss and cognitive decline, are viewed as natural signs of aging. This frequently causes the disease to be diagnosed in an advanced stage. Individuals' reluctance to bring up cognitive issues with other family members and friends postpones the timely diagnosis of the illness. In order to diagnose the disease early, it is necessary to increase public awareness of the condition and to encourage people to talk about their cognitive issues sooner. To do this, organizations supporting and educating patients with Alzheimer's disease include the Alzheimer's Association and The Alzheimer's Foundation of America.

There are numerous additional programs to raise disease awareness in the local community. In addition to conducting extensive education, training, and outreach programs in numerous US communities, the funded projects offered interventions that were supported by evidence and informed by evidence. The National Alzheimer's Plan, AFA Teens, The Alzheimer's Association Walk to End Alzheimer's, and The Hampden Good Neighbor Program are just a few of the additional public initiatives and programs related to Alzheimer's that exist in the US. Additionally, some public initiatives and programs are hosted in Europe, including INDUCT, MinD, AMYPAD, and MOPEAD. These programs also undertake a number of initiatives to raise disease awareness on a global scale. Therefore, such efforts will contribute to the growth of the global market during the forecast period.

Significant Alzheimer's Disease Therapeutics Market Trend

The availability of highly sensitive diagnostic modalities is an emerging trend in the market growth. The debilitating and incurable condition known as Alzheimer's disease causes the progressive degeneration or death of nerve cells. Both the patient's and the caregivers' quality of life is significantly impacted. The burden of treating diseases is lessened by the creation of sophisticated diagnostic tools that can detect disease manifestation in its earliest stages and facilitate early treatment decisions. One technique for the early diagnosis of this disease is neuroimaging.

Preclinical stages of Alzheimer's disease progress into advanced clinical stages. Therefore, diagnostic tools are crucial for efficient disease management through the tracking of disease development, timely administration of therapeutics, and assessment of therapeutic efficacy. There are numerous ways to diagnose the illness, but new approaches that accurately reflect how the brain works are needed. Breath testing has the potential to significantly improve disease diagnosis as a new non-invasive diagnostic tool. The foundation of this approach is the evaluation of metabolic alterations and the quantification of volatile compound concentrations in exhaled breath models. Therefore, the development of such innovative diagnostic modalities will drive the growth of the global market during the forecast period.

Major Alzheimer's Disease Therapeutics Market Challenge

Challenges associated with the diagnosis of alzheimer's disease are major issues impeding market growth. The clinical challenge still lies in identifying the disease at an early stage. Prior to the first sign of clinical impairment, the disease's neuropathological changes in the brain begin to build up 10-15 years. The final stage of the disease is dementia. Patients may exhibit subjective cognitive impairment, seemingly unrelated cognitive changes, and personality changes, such as depressive state and changes in social behavior, at an early stage of the disease but not necessarily clinical signs of dementia. All of these changes may have other causes.

Currently, a thorough neuropsychological assessment and blood sample analysis are used to diagnose the disease. High inter- and intra-laboratory variation do exist, though. As a result, even when using the same approaches, different centers have different cutoffs for pathological levels. The main drawback of the current approaches is that there are fewer effective markers for each stage of the disease. Additionally, the accuracy of diagnosis is limited because some clinical settings do not have access to more sophisticated techniques like PET-amyloid. Additionally, particularly in the elderly population, the data on neuropathological processes in Alzheimer's disease and normal aging are not fully understood. Therefore, the abovementioned factors may pose a challenge to the growth of the market during the forecast period. 

Key Alzheimer's Disease Therapeutics Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Alzheimers Disease Therapeutics Market Customer Landscape

Who are the Major Alzheimer's Disease Therapeutics Market Vendors?

Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

AB Science SA - The company manufactures and distributes medical drugs and equipment in various parts of the world. The key offerings of the company include alzheimer's disease therapeutics such as Masitinib.

The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:

• AbbVie Inc.
• AgeneBio Inc.
• Aurobindo Pharma Ltd.
• Biogen Inc.
• Denali Therapeutics Inc.
• Eisai Co. Ltd.
• Eli Lilly and Co.
• Grifols SA
• H Lundbeck AS
• Johnson and Johnson Services Inc.
• Neuronascent Inc.
• Novartis AG
• Shanghai Green Valley Pharmaceuticals Co. Ltd.
• Spinogenix Inc.
• T3D Therapeutics

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

What is the Fastest-Growing Segment in the Alzheimer's Disease Therapeutics Market?

The market share growth by the cholinesterase segment will be significant during the forecast period. The most prevalent age-related neurodegenerative disease, Alzheimer's disease, has emerged as a pressing global public health issue. Significant strides have been made in understanding the disease's fundamental neurobiology, which has made it possible to treat the condition with new drugs. One of them is cholinesterase inhibitors.

Get a glance at the market contribution of various segments View the PDF Sample

The cholinesterase segment was valued at USD 3,433.43 million in 2017 and continued to grow until 2021. An essential therapeutic target for the condition is the enzyme cholinesterase. The main factors contributing to the decline in cognitive abilities in disease patients are the degeneration of cholinergic neurons in the brain and the loss of neurotransmission. A decrease in acetylcholine synthesis is another major contributor to the illness. As a result, one of the potential therapeutic approaches is to raise cholinergic levels in the brain by preventing acetylcholinesterase from performing its biological function. Cholinesterase inhibitors are now the main method used to treat the symptoms of Alzheimer's disease because they increase the amount of acetylcholine that is available in central synapses. Cholinesterase inhibitors are therefore widely used in the symptomatic treatment of Alzheimer's disease as a result of their high efficacy. There are three approved cholinesterase inhibitors (donepezil, galantamine, and rivastigmine) available for the treatment of the disease. These drugs slightly delay the loss of mental abilities in individuals with mild-to-moderate Alzheimer's disease.  Therefore, the availability, high efficacy, and safety of cholinesterase inhibitors in treating symptoms of the disease will drive the growth of the segment during the forecast period. 

Which are the Key Regions for the Alzheimer's Disease Therapeutics Market?

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 37% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

Because of its high prevalence of Alzheimer's disease and rising disease awareness, North America commands the largest share of the global market. In the developed nations of the region, the disease's prevalence has been rising noticeably. By 2060, the US is expected to have twice as many cases of the disease and its associated dementia, according to the Centers for Disease Control and Prevention (CDC). By 2060, it is anticipated that this burden will increase to 13.9 million people or 3.3% of the US population. This will have a positive effect on the market growth in the region. 

The mortality rate has increased as a result of the majority of people with Alzheimer's disease being ignorant of the condition and available treatments. Therefore, it has become essential to spread awareness of the disease through a variety of initiatives. The Alzheimer's Association and the Alzheimer's Society of Canada are two US and Canadian organizations that concentrate on spreading awareness of Alzheimer's disease. Additionally, the market will continue to grow during the forecast period as a result of the rising funding for the development of novel therapeutics to treat the disease.

The absence of effective treatments for Alzheimer's disease forces vendors to invest heavily in research in this field, which will sustain the market's expansion during the forecasted period. In order to assess the safety and effectiveness of gene therapy AAV-hTERT for the treatment of the disease, for instance, Libella Gene Therapeutics is carrying out a Phase I clinical trial. These advancements in the study of curative therapies, which promise high safety and efficacy, will therefore aid the market growth during the forecast period.

The outbreak of COVID-19 negatively impacted the growth of the regional market in 2020. However, in 2021, the initiation of large-scale vaccination drives and other government initiatives resulted in the lifting of lockdowns. This resulted in an increase in new and rescheduled medical procedures, including Alzheimer's disease cases, which has led to an increase in demand for the disease's therapeutics in the region. Hence, the increasing adoption of Alzheimer's disease therapeutics, a rise in the prevalence of Alzheimer's disease, a rise in healthcare expenditure, and an increase in the number of advanced healthcare facilities are expected to recover and stabilize the growth of the market in the region during the forecast period.

Segment Overview

The report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

• Drug Class Outlook (USD Million, 2017 - 2027)
  • Cholinesterase inhibitors
  • N-methyl-D-aspartate receptor antagonist
  • Others

• Distribution Channel Outlook (USD Million, 2017 - 2027)
  • Hospital pharmacy
  • Retail pharmacy
  • E-commerce pharmacy

• Region Outlook (USD Million, 2017 - 2027)
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
    • Vietnam
    • Others
  • Rest of World
    • Saudi Arabia
    • South Africa
    • Brazil
    • Others

Parent Market Analysis

Technavio categorizes the global Alzheimer's disease therapeutics market as a part of the pharmaceutical market within the overall healthcare industry. The parent pharmaceuticals market covers products and companies engaged in the R and D or production of generic drugs, non-generic drugs, and veterinary drugs.   Our research report has extensively covered external factors influencing the parent market growth during the forecast period.

View the PDF sample

What are the Key Data Covered in this Alzheimers Disease Therapeutics Market Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the alzheimer's disease therapeutics market between 2023 and 2027
• Precise estimation of the size of the alzheimer's disease therapeutics market size and its contribution to the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of alzheimer's disease therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch